IND Safety Reporting: Stakeholders Tussle Over Which Adverse Events To Report, Proper Oversight Body
Executive Summary
US FDA officials, drug sponsors discussing creation of library of adverse event rates.
You may also be interested in...
US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says
FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.
IND Safety Analysis Requires Broader Unblinding Of Reports, FDA Advises
Sponsors should create safety assessment committees, draft guidance recommends.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.